Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-In-Human PainCart Study for STR-324

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03430232
Recruitment Status : Completed
First Posted : February 12, 2018
Last Update Posted : December 12, 2018
Sponsor:
Information provided by (Responsible Party):
Stragen France

Brief Summary:
This is an interventional, first-in-man study, double-blind, placebo-controlled, two-part, ascending doses study to investigate the safety, tolerability and efficacy of STR-324 infusions in healthy volunteers.

Condition or disease Intervention/treatment Phase
Pain Drug: Placebo Drug: STR-324 Dose Level 1 Drug: STR-324 Dose Level 2 Drug: STR-324 Dose Level 3 Drug: STR-324 Dose Level 4 Drug: STR-324 Dose Level 5 Drug: STR-324 Dose Level 6 Drug: STR-324 Dose Level 7 Drug: STR-324 Dose Level 8 Drug: STR-324 Dose Level A Drug: STR-324 Dose Level B Drug: STR-324 Dose Level C Phase 1

Detailed Description:
Part I : ascending doses of short lasting infusion Part II : ascending doses of long lasting infusion

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: For part I: crossover model For part II: parallel model
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A First-in-Human, Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STR-324 in Healthy Subjects
Actual Study Start Date : February 20, 2018
Actual Primary Completion Date : November 7, 2018
Actual Study Completion Date : November 7, 2018

Arm Intervention/treatment
Experimental: Part I (Panel 1): STR-324 or placebo
Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
Drug: Placebo
Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Drug: STR-324 Dose Level 1
Short infusion of a solution for intravenous administration

Drug: STR-324 Dose Level 3
Short infusion of a solution for intravenous administration

Drug: STR-324 Dose Level 5
Short infusion of a solution for intravenous administration

Drug: STR-324 Dose Level 7
Short infusion of a solution for intravenous administration

Experimental: Part I (Panel 2): STR-324 or placebo
Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
Drug: Placebo
Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Drug: STR-324 Dose Level 2
Short infusion of a solution for intravenous administration

Drug: STR-324 Dose Level 4
Short infusion of a solution for intravenous administration

Drug: STR-324 Dose Level 6
Short infusion of a solution for intravenous administration

Drug: STR-324 Dose Level 8
Short infusion of a solution for intravenous administration

Experimental: Part II (Panel 1): STR-324 or placebo
Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
Drug: STR-324 Dose Level A
Long infusion of a solution for intravenous administration

Drug: Placebo
Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Experimental: Part II (Panel 2): STR-324 or placebo
Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
Drug: STR-324 Dose Level B
Long infusion of a solution for intravenous administration

Drug: Placebo
Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%

Experimental: Part II (Panel 3): STR-324 or placebo
Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
Drug: STR-324 Dose Level C
Long infusion of a solution for intravenous administration

Drug: Placebo
Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%




Primary Outcome Measures :
  1. Safety and tolerability: number of subjects who experience (serious) treatment emergent adverse events, potential clinically changes in vital signs, ECG, holter, physical examinations, laboratory tests and urine production [ Time Frame: Day 7 (+/- 2 days) post dosing ]

Secondary Outcome Measures :
  1. Parts I and II: Maximum plasma concentration (Cmax) [ Time Frame: Up to 24 hours for Part I and up to 52 hours for Part II ]
  2. Parts I and II:Time to maximum plasma concentration (Tmax) [ Time Frame: Up to 24 hours for Part I and up to 52 hours for Part II ]
  3. Parts I and II: Area under the plasma concentration-time curve from zero to infinity(AUC0-inf) [ Time Frame: Up to 24 hours for Part I and up to 52 hours for Part II ]
  4. Parts I and II: Area under the plasma concentration-time curve from zero to the last measured concentration above the limit of quantification (AUC0-last) [ Time Frame: Up to 24 hours for Part I and up to 52 hours for Part II ]
  5. Parts I and II: Terminal disposition rate constant (λz) with the respective half-life (t½) [ Time Frame: Up to 24 hours for Part I and up to 52 hours for Part II ]
  6. Parts I and II: Amount excreted in urine in 24 hours [ Time Frame: Up to 24 hours for Part I and up to 72 hours for Part II ]
  7. Parts I and II: Thermal Pain [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  8. Parts I and II: Electrical pain Stair and Burst [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  9. Parts I and II: Pressure Pain [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  10. Parts I and II: Cold Pressor [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  11. Parts I and II: Conditioned Pain Modulation Response (change from electrical stair pre- and post-cold pressor) [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  12. Parts I and II: Visual Analogue Scale Bond & Lader [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  13. Parts I and II: Visual Analogue Scale Bowdle [ Time Frame: Up to 5 hours for part I and up to 56 hours for part II ]
  14. Part II only: Saccadic eye movement [ Time Frame: Up to 56 hours ]
  15. Part II only: Smooth pursuit eye movement [ Time Frame: Up to 56 hours ]
  16. Part II only: Adaptive tracking [ Time Frame: Up to 56 hours ]
  17. Part II only: Body sway [ Time Frame: Up to 56 hours ]
  18. Part II only: N-Back [ Time Frame: Up to 56 hours ]
  19. Part II only: Pharmaco-EEG: power [ Time Frame: Up to 56 hours ]
  20. Part II only: Pupillometry [ Time Frame: Up to 56 hours ]
  21. Part II only: 49-item Addiction Center Research Inventory [ Time Frame: Up to 60 hours ]
  22. Part II only: Bowel Function Index [ Time Frame: Up to day 7 ]
  23. Part II - Groups 2 and 3 only: Thermal pain (Normal skin and erythema skin - UVB) [ Time Frame: Up to 24 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent prior to any study-mandated procedure
  • Healthy male subjects, 18 to 45 years of age, inclusive at screening.
  • Body mass index (BMI) between 18 and 30 kg/m2, inclusive at screening, and with a minimum weight of 50 kg.
  • All males must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study treatment.
  • Has the ability to communicate well with the Investigator in the Dutch language and willing to comply with the study restrictions.

Exclusion Criteria:

  • Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator
  • Subject with clinically significant abnormalities in blood pressure, heart rate, ECG recording and laboratory parameters
  • Abnormal renal function (eGFR (MDRD) < 60 mL/min/1.73m2).
  • Previous history of seizures or epilepsy.
  • Acute disease state (e.g. nausea, vomiting, fever, or diarrhea) within 7 days before the first study day.
  • Positive Hepatitis B surface antigen (HBsAg), Hepatitis B antibodies, Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab)
  • Use of any medications (prescription or over-the-counter [OTC]), within 14 days of study drug administration, or less than 5 half-lives (whichever is longer).
  • Use of any vitamin, mineral, herbal, and dietary supplements within 7 days of study drug administration, or less than 5 half-lives (whichever is longer).
  • Participation in an investigational drug or device study within 3 months prior to first dosing.
  • History of abuse of addictive substances or current use of substances (alcohol, illegal substances)
  • Positive test for drugs of abuse or alcohol breath test at screening or pre-dose.
  • Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug, or multiple drug allergies (non-active hay fever is acceptable).
  • Loss or donation of blood over 500 mL within three months prior to screening
  • Any current, clinically significant, known medical condition in particular any existing conditions that would affect sensitivity to cold or pain

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03430232


Locations
Layout table for location information
Netherlands
CHDR
Leiden, Netherlands, 2333
Sponsors and Collaborators
Stragen France
Layout table for additonal information
Responsible Party: Stragen France
ClinicalTrials.gov Identifier: NCT03430232    
Other Study ID Numbers: STR-324-CL-039
2014-002402-21 ( EudraCT Number )
First Posted: February 12, 2018    Key Record Dates
Last Update Posted: December 12, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No